Highly Potent APIs

Request Information

Interested in a certain contract manufacturing service or technology? Fill out the form below and we will provide you with the information you need.

Our SafeBridge^®-certified facilities in Madison and Verona, Wisconsin maintain a complete range of kilo labs, pilot plants, and commercial capabilities for the manufacture of HPAPIs down to single-digit nanogram containment levels, featuring appropriate room pressurization, airlocks, ventilation, and isolators to properly handle these materials. We combine industry-leading expertise in HPAPI and biologics to commercialize high-potent conjugates.

HPAPI offer to support ADC manufacturing

DM1-Mertansine and MAYCore™ Intermediates for your drug conjugate programs are now available without licensing or royalty fees. We maintain an available stock to support your drug conjugation projects and accelerate your development timelines. Our proprietary maytansinoid synthesis can be modified to meet your specific linker-payload needs. Features include:

• High purity material
• Samples available free of charge
• Merck-owned DMF/ASMF for regulatory filings
• Validated analytical methods

DOLCore™ is an advanced intermediate through which all known dolastatin 10 payloads can be made. This proprietary technology gives you added flexibility to make new or established dolastatins and can be modified to meet your specific linker-payload needs. DOLCore™ provides exceptional time benefits by reducing the number of steps in the custom synthesis pathway. Advantages of our DOLCore™ platform include speed to market and reduced supply chain complexity. We also offer phase appropriate regulatory support, free licensing agreements, and no royalty payments.

We are confident that this innovative solution will meet your critical timeline needs and get your program to the clinic faster.

Features include:

• No chromatography. i.e. timely in-house cGMP process
• Supply chain risk reduction – stock readily available
• 5 g samples available free of charge

Pyrrolobenzodiazepines (PBDs) are an up-and-coming class of payloads, with the first commercial PBDbased ADC launched in 2021. PBDCore™ Intermediate contains the active structural components of PBDs, giving our customers the flexibility to make most PBD payloads.

In addition, our ADC manufacturing facility in St. Louis, Missouri is specifically designed for conjugation of HPAPIs to antibodies or other therapeutic proteins used as targeted therapies. The first commercial ADC facility in North America, it offers dedicated high-containment suites that meet all standards for current good manufacturing practices (cGMP) and has been SafeBridge^®-certified since 2009.

Related Product Resources

Flyer: Maytansinoid Products for Your Drug Conjugate Program
Flyer: Simplify Your Synthesis with ADCore™ Payload Intermediates
Flyer: ADC Express™ Pre-clinical Conjugation Services for the Best Candidate Selection
Flyer: ChetoSensar: Consider it DisSolved
Flyer: Highly Potent and Complex API Manufacturing
Webinar: Chasing the Nanogram Limit
White Paper: Use of Payload Core Compounds to Accelerate ADC Clinical Development Timelines
Webinar: Payload Core Product Line Accelerates ADC Clinical Timelines
Flyer: Link & Load Smarter - Discover comprehensive ADC Solutions
ADC Payload Intermediates and virtual HPAPI Site Tour

World-Class Facilities Provide Supply Chain Confidence

The global footprint of our API contract manufacturing services assures you wide-ranging regulatory and supply expertise, easily accessed through a single trusted partner.

Our API Contract Manufacturing Facility Locations

• Madison, Wisconsin, USA (cGMP)
  
• St. Louis, Missouri, USA (cGMP)
• Sheboygan, Wisconsin, USA (non-cGMP)
• Schaffhausen, Switzerland (cGMP)